Chemotherapy for the Treatment of Alveolar Echinococcosis: Where Are We?

Overview

Journal Parasite

Specialty Parasitology

Date 2024 Sep 23

PMID 39311470

Authors

Brice Autier

Florence Robert-Gangneux

Sarah Dion

Affiliations

Soon will be listed here.

Abstract

Alveolar echinococcosis (AE) is a severe liver disease due to infection with the Echinococcus multilocularis larval stage, called the metacestode. Management of AE is based on benzimidazole chemotherapy (albendazole or mebendazole), associated with surgery when possible. Benzimidazoles are the only compounds recommended for the treatment of AE; however, these are parasitostatic, which means that the parasite can resume growth when treatment is interrupted. Also, benzimidazoles can cause liver dysfunction which may prevent their use. Numerous drugs have been reported to have in vitro activity against E. multilocularis, but few had satisfactory in vivo activity, and none were clearly more effective than benzimidazoles. These drugs belong to various therapeutic categories including anti-infective agents (e.g. amphotericin B, mefloquine, pentamidine derivatives), anti-neoplastic compounds (e.g. imatinib, nilotinib, bortezomib), plant-extracted compounds (e.g. thymol, crocin, carvacrol) and others (e.g. metformin, verapamil, thiaclopride). These treatments are generally of limited interest due to their toxicity, their unfavorable pharmacokinetics, or the scarcity of studies involving humans. Apart from benzimidazoles, only amphotericin B, mefloquine and nitazoxanide have been reported to be used for human AE treatment, with unsatisfactory results. Few studies have aimed at developing innovative strategies for AE drug therapy, such as vectorization of drugs using nanoparticles. Altogether, this review emphasizes the urgent need for new therapeutic strategies in AE management, for which there is currently no curative chemotherapy.

References

Fabbri J, Pensel P, Albani C, Lopez L, Simonazzi A, Bermudez J . Albendazole solid dispersions against alveolar echinococcosis: a pharmacotechnical strategy to improve the efficacy of the drug. Parasitology. 2020; 147(9):1026-1031. PMC: 10317690. DOI: 10.1017/S0031182020000670. View

Kuster T, Stadelmann B, Aeschbacher D, Hemphill A . Activities of fenbendazole in comparison with albendazole against Echinococcus multilocularis metacestodes in vitro and in a murine infection model. Int J Antimicrob Agents. 2014; 43(4):335-42. DOI: 10.1016/j.ijantimicag.2014.01.013. View

Joo H, Lee J, Maskery B, Park C, Alpern J, Phares C . The Effect of Drug Pricing on Outpatient Payments and Treatment for Three Soil-Transmitted Helminth Infections in the United States, 2010-2017. Am J Trop Med Hyg. 2021; 104(5):1851-1857. PMC: 8103488. DOI: 10.4269/ajtmh.20-1452. View

Stettler M, Fink R, Walker M, Gottstein B, Geary T, Rossignol J . In vitro parasiticidal effect of Nitazoxanide against Echinococcus multilocularis metacestodes. Antimicrob Agents Chemother. 2003; 47(2):467-74. PMC: 151752. DOI: 10.1128/AAC.47.2.467-474.2003. View

Eberhardt N, Peters L, Kapp-Schwoerer S, Beer M, Beer A, Gruner B . 18F-FDG-PET/MR in Alveolar Echinococcosis: Multiparametric Imaging in a Real-World Setting. Pathogens. 2022; 11(3). PMC: 8951377. DOI: 10.3390/pathogens11030348. View

Mitchell M, Billingsley M, Haley R, Wechsler M, Peppas N, Langer R . Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2020; 20(2):101-124. PMC: 7717100. DOI: 10.1038/s41573-020-0090-8. View

Reuter S, Beisler T, Kern P . Combined albendazole and amphotericin B against Echinococcus multilocularis in vitro. Acta Trop. 2010; 115(3):270-4. DOI: 10.1016/j.actatropica.2010.04.009. View

Jelicic K, Papic N, Viskovic K, Vince A . Case Report: Amphotericin B and Mefloquine as a Salvage Treatment of Alveolar Echinococcosis. Am J Trop Med Hyg. 2023; 108(3):581-583. PMC: 9978558. DOI: 10.4269/ajtmh.22-0465. View

Ingold K, BIGLER P, Thormann W, Cavaliero T, Gottstein B, Hemphill A . Efficacies of albendazole sulfoxide and albendazole sulfone against In vitro-cultivated Echinococcus multilocularis metacestodes. Antimicrob Agents Chemother. 1999; 43(5):1052-61. PMC: 89110. DOI: 10.1128/AAC.43.5.1052. View

10.

Xin Q, Yuan M, Li H, Song X, Lu J, Jing T . In vitro effects of lonidamine and 6-aminonicotinamide against Echinococcus granulosussensu stricto and Echinococcus multilocularis. Vet Res. 2020; 51(1):29. PMC: 7045558. DOI: 10.1186/s13567-020-00744-6. View

11.

Wen H, New R, Muhmut M, Wang J, Wang Y, Zhang J . Pharmacology and efficacy of liposome-entrapped albendazole in experimental secondary alveolar echinococcosis and effect of co-administration with cimetidine. Parasitology. 1996; 113 ( Pt 2):111-21. DOI: 10.1017/s003118200006635x. View

12.

Taylor D, Morris D, Richards K, Reffin D . Echinococcus multilocularis: in vivo results of therapy with albendazole and praziquantel. Trans R Soc Trop Med Hyg. 1988; 82(4):611-5. DOI: 10.1016/0035-9203(88)90528-7. View

13.

Nagy J, Schipper H, Koopmans R, Butter J, van Boxtel C, Kager P . Effect of grapefruit juice or cimetidine coadministration on albendazole bioavailability. Am J Trop Med Hyg. 2002; 66(3):260-3. DOI: 10.4269/ajtmh.2002.66.260. View

14.

Enkai S, Kouguchi H, Inaoka D, Irie T, Yagi K, Kita K . In vivo efficacy of combination therapy with albendazole and atovaquone against primary hydatid cysts in mice. Eur J Clin Microbiol Infect Dis. 2021; 40(9):1815-1820. PMC: 8346398. DOI: 10.1007/s10096-021-04230-5. View

15.

Stadelmann B, Aeschbacher D, Huber C, Spiliotis M, Muller J, Hemphill A . Profound activity of the anti-cancer drug bortezomib against Echinococcus multilocularis metacestodes identifies the proteasome as a novel drug target for cestodes. PLoS Negl Trop Dis. 2014; 8(12):e3352. PMC: 4256282. DOI: 10.1371/journal.pntd.0003352. View

16.

Lotsch F, Waneck F, Auer H, Kaczirek K, Karanikas G, Ramharter M . FDG-PET/MRI in alveolar echinococcosis. Int J Infect Dis. 2017; 64:67-68. DOI: 10.1016/j.ijid.2017.09.006. View

17.

Lacey E . Mode of action of benzimidazoles. Parasitol Today. 1990; 6(4):112-5. DOI: 10.1016/0169-4758(90)90227-u. View

18.

Bartholomot G, Vuitton D, Harraga S, Shi D, Giraudoux P, Barnish G . Combined ultrasound and serologic screening for hepatic alveolar echinococcosis in central China. Am J Trop Med Hyg. 2002; 66(1):23-9. DOI: 10.4269/ajtmh.2002.66.23. View

19.

Lassegue A, Estavoyer J, Minazzi H, Barale T, Gillet M, Vuitton D . [Treatment of human alveolar echinococcosis with flubendazole. Clinical, morphological and immunological study]. Gastroenterol Clin Biol. 1984; 8(4):314-20. View

20.

Stettler M, Rossignol J, Fink R, Walker M, Gottstein B, Merli M . Secondary and primary murine alveolar echinococcosis: combined albendazole/nitazoxanide chemotherapy exhibits profound anti-parasitic activity. Int J Parasitol. 2004; 34(5):615-24. DOI: 10.1016/j.ijpara.2004.01.006. View